AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Hansa Biopharma AB
Video analysis: HNSBF
All videosNo video analysis for this stock yet. Request one from our team.
News: HNSBF
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
LUND, Sweden, Aug. 18, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA). "This first commercial living donor transplant patient in Australia represents an important milestone for Hansa and for patients facing significant barriers to transplantation," said Renée Aguiar-Lucander, CEO of Hansa Biopharma.
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
Hansa Biopharma AB (publ) (HNSBF) Q2 2026 Earnings Call Transcript
Hansa Biopharma participating in Wedbush PacGrow Renal Summit
LUND, Sweden, July 2, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Maria Törnsén, COO and President U.S., Hansa Biopharma, will participate in a fireside chat titled "Don't Be So Sensitive - Bringing Kidneys to the Over-Sensitized" with Dr. Leonardo Riella, Massachusetts General Hospital, at the Wedbush PacGrow Renal Summit in Boston, at 1:10 PM EDT on Wednesday, July 8, 2026. If you are interested in meeting with Hansa's management, please contact Hansa Biopharma at ir@hansabiopharma.com.
Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region The transaction significantly strengthens Hansa's financial position and enables a robust US launch, subject to US approval of imlifidase LUND, Sweden, July 1, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ Stockholm: HNSA) and SERB S.A. ("SERB") today announced required regulatory approvals have been obtained and that the previously announced exclusive licensing transaction with SERB has closed.
Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
Hansa Biopharma AB (publ) (HNSBF) Analyst/Investor Day Transcript
